Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy
Authors:
- Francesco BartoliFBFrancesco Bartoli
- Philip ElsingaPEPhilip Elsinga
- Luiza Reali NazarioLNLuiza Reali Nazario
- Aureliano ZanaAZAureliano Zana
- Andrea GalbiatiAGAndrea Galbiati
- Jacopo MillulJMJacopo Millul
- Francesca MiglioriniFMFrancesca Migliorini
- Samuele CazzamalliSCSamuele Cazzamalli
- Dario NeriDNDario Neri
- Riemer H. J. A. SlartRiemer H. J. A. Slart
- Paola Anna ErbaPEPaola Anna Erba
Open Access
- 2 August 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 15 (8) , 958
Abstract
FAP-targeted radiopharmaceuticals represent a breakthrough in cancer imaging and a viable option for therapeutic applications. OncoFAP is an ultra-high-affinity ligand of FAP with a dissociation constant of 680 pM. OncoFAP has been recently discovered and clinically validated for PET imaging procedures in patients with solid malignancies. While more and more clinical validation is becoming available, the need for scalable and robust procedures for the preparation of this new class of radiopharmaceuticals continues to increase. In this article, we present the development of automated radiolabeling procedures for the preparation of OncoFAP-based radiopharmaceuticals for cancer imaging and therapy. A new series of [68Ga]Ga-OncoFAP, [177Lu]Lu-OncoFAP and [18F]AlF-OncoFAP was produced with high radiochemical yields. Chemical and biochemical characterization after radiolabeling confirmed its excellent stability, retention of high affinity for FAP and absence of radiolysis by-products. The in vivo biodistribution of [18F]AlF-NOTA-OncoFAP, a candidate for PET imaging procedures in patients, was assessed in mice bearing FAP-positive solid tumors. The product showed rapid accumulation in solid tumors, with an average of 6.6% ID/g one hour after systemic administration and excellent tumor-to-healthy organs ratio. We have developed simple, quick, safe and robust synthetic procedures for the preparation of theranostic OncoFAP-compounds based on Gallium-68, Lutetium-177 and Fluorine-18 using the commercially available FASTlab synthesis module.Keywords
Funding Information
- Philogen
This publication has 50 references indexed in Scilit:
- Matching chelators to radiometals for radiopharmaceuticalsChemical Society Reviews, 2013
- Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomographyApplied Radiation and Isotopes, 2013
- Antioxidant activity and free radical scavenging reactions of gentisic acid:in-vitroand pulse radiolysis studiesFree Radical Research, 2011
- Inorganic approaches for radiolabelling biomolecules with fluorine-18 for imaging with Positron Emission TomographyDalton Transactions, 2011
- Gallium(III) Complexes of DOTA and DOTA−Monoamide: Kinetic and Thermodynamic StudiesInorganic Chemistry, 2010
- A Novel Method of 18F Radiolabeling for PETJournal of Nuclear Medicine, 2009
- Fluorine-18 and medical imaging: Radiopharmaceuticals for positron emission tomographyJournal of Fluorine Chemistry, 2006
- Generation of human high‐affinity antibodies specific for the fibroblast activation protein by guided selectionEuropean Journal of Biochemistry, 2001
- Human antibody derivatives against the fibroblast activation protein for tumor stroma targeting of carcinomasInternational Journal of Cancer, 2001
- Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patientsBritish Journal of Clinical Pharmacology, 2001